Home > Insider Trading > Filing (0000905718-17-000831)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1582554	Matinas Biopharma Holdings Inc.	MTNB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1403497	K Adam Stern	Aegis Capital Corp, Attn: Cassel Shapiro 810 7Th Avenue 18Th Floor New York NY 10019		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2017-09-07	50,000	$1.38	3,639,483	No	4	P	Indirect	Held by AKS Family Partners LP
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2017-09-08	50,000	$1.38	3,689,483	No	4	P	Indirect	Held by AKS Family Partners LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Held by AKS Family Partners LP
No	4	P	Indirect	Held by AKS Family Partners LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	793,992	Direct
Common Stock, Par Value $0.0001 Per Share	300,000	Indirect	Held by Pavilion Capital Partners Inc.
Common Stock, Par Value $0.0001 Per Share	300,000	Indirect	Held by Piper Ventures Partners LLC
Common Stock, Par Value $0.0001 Per Share	1,000,000	Indirect	Held by AKS Family Foundation
Common Stock, Par Value $0.0001 Per Share	600,000	Indirect	Held by SternAegis Ventures LLC Defined Benefit Pension Plan

Footnotes

Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.40, inclusive. The reporting person undertakes to provide Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.39, inclusive. The reporting person undertakes to provide Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.